Recordati Industria Chimica e Farmaceutica went into this earnings print with the stock flat over the past week and only modestly higher over three months, hardly the profile of a market darling. Yet the headline from Q2 is clear: the rare disease engine is doing the heavy lifting while profitability looks tighter quarter on quarter.
Revenue in Q2 landed at €697.4m with basic earnings per share of €0.57 and net income of €116.6m. That sits below Q1 levels but fits into a half year in which rare disease and United States growth, along with confirmed full year guidance, remain the core story that investors will now test against the current €51.4 share price.
Love Recordati Industria Chimica e Farmaceutica's rare disease engine but concerned about the tighter quarter on quarter profitability? Take a look at our screener of resilient companies with strong balance sheets and fundamentals through the list of solid balance sheet and fundamentals stocks (422 results)
Q2 2026 Earnings Summary
- Revenue (Q2 2026 vs Q2 2025): €697.4m vs €643.9m (up about 8.3%)
- Net Income (Excl. Extra Items, Q2 2026 vs Q2 2025): €116.6m vs €91.1m (up about 28.0%)
- Basic EPS (Q2 2026 vs Q2 2025): €0.57 vs €0.44 (up about 29.5%)
- Rare Disease pipeline, Products in Phase II (Q2 2026 vs Q1 2026): 1 vs 1 (stable quarter on quarter)
Tired of scrolling through dense earnings tables and raw figures to make sense of Recordati Industria Chimica e Farmaceutica? Get a clear visual view of the company’s valuation and overall financial picture in the company report for Recordati Industria Chimica e Farmaceutica.
Recordati bull case: rare disease engine on track
Bulls argue Recordati can lean on rare disease to drive faster growth and better margins as the mix shifts toward Isturisa, Enjaymo and other specialist brands. H1 numbers largely back that up. Rare Disease revenue of €604m grew 17.1% reported and 22% at constant FX, clearly ahead of the group. Isturisa grew 58% year on year and management highlighted more than 20% better conversion from enrollments to commercial starts in Q2, which speaks directly to the thesis around improved diagnosis, access and U.S. field execution. U.S. revenue rose 29.5% reported and 38.2% in local currency, again aligning with the idea that U.S. endocrinology is the main growth vector. EBITDA of €540m grew faster than revenue, which suggests the high margin mix is helping, even while the company continues to spend behind Isturisa and new launches.
Recordati bear case: margin strain and FX risks persist
Bears worry that Recordati will pay a high price for rare disease growth, with FX, litigation and primary care headwinds eating into the benefits. There is some support for that caution. Net income in Q2 of €116.6m and basic EPS of €0.57 sit below Q1, while management flagged higher net financial expenses from unrealized USD FX losses. That validates the concern that currency can dilute reported earnings even when local trends look solid. Specialty and Primary Care revenue of €774m was broadly flat on a like for like basis, with losses from Cardicor and a weaker cough and cold season only partly balanced by Vazkepa and other promoted brands. The strong Eligard lift in Turkey is partly tied to a temporary competitor stock out, so some of that support may unwind, which keeps the sustainability of SPC margins an open question.
Compare Recordati Industria Chimica e Farmaceutica's rare disease momentum and margin questions with what the street is pricing in right now. See the consensus price target analysis for Recordati Industria Chimica e FarmaceuticaStay Ahead Of Your Next Move
If Recordati Industria Chimica e Farmaceutica's mix of rare disease growth and tighter profitability has your attention, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and watch how the thesis develops. When you decide to build or adjust a position, use the Portfolio Command Center to cut through noise and focus on the key updates that matter for your holdings. For a broader view on what other investors are seeing around Recordati Industria Chimica e Farmaceutica and similar stocks, tap into the Community and compare different perspectives. This way you can spot potential catalysts and emerging risks early and stay a step ahead of the market.
Seeking Alternatives Beyond Recordati Industria Chimica E Farmaceutica
Fresh stock ideas move fast. Some are building quiet breakout momentum under the radar for now. Others may be dropping into better entry zones. Do not wait and consider getting in early.
- Spot potential income anchors that aim to keep paying while others stall by scanning the curated 439 dividend fortresses before the crowd catches on.
- Target companies pushing AI adoption across real world infrastructure with the hand picked 56 AI infrastructure stocks while the strongest momentum is still building.
- Track opportunities tied to long term energy trends and grid upgrades through a focused set of 34 power grid technology and infrastructure stocks before these stories are fully priced in.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com